Patents Represented by Attorney, Agent or Law Firm Linda Judge, Esq.
  • Patent number: 6676935
    Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: January 13, 2004
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur
  • Patent number: 6495130
    Abstract: The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: December 17, 2002
    Assignee: Calydon, Inc.
    Inventors: Daniel R. Henderson, De Chao Yu
  • Patent number: 6489162
    Abstract: The present invention relates to a method for producing helper-free stocks of recombinant adeno-associated virus (rAAV) which can be used to efficiently and stably transduce foreign genes into host cells or organisms. The method comprises the cotransfection of eukaryotic cells with rAAV and with helper AAV DNA in the presence of helper virus (e.g. adenovirus or herpesvirus) such that the helper AAV DNA is not associated with virion formation. The crux of the invention lies in the inubility of the helper AAV DNA to recombine with rAAV vector, thereby preventing the generation of wild-type virus. In a specific embodiment of the invention, the vector comprises a recombinant AAV genome containing only the terminal regions of the AAV chromosome bracketing a non-viral gene, and the helper AAV DNA comprises a recombinant AAV genome containing that part of the AAV genome which is not present in the vector, and in which the AAV terminal regions are replaced by adenovirus sequences.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: December 3, 2002
    Assignee: The Trustees of Princeton University
    Inventors: Thomas E. Shenk, Richard Jude Samulski, Long-Sheng Chang
  • Patent number: 6436394
    Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise and adenoviral gene under control of a transcription regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: August 20, 2002
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu